Evidence map›Paper›PMID 15889186›Full record

ArticleOrganic & biomolecular chemistry2005

Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality.

Pedro Besada, Liaman Mamedova, Craig J Thomas, Stefano Costanzi, Kenneth A Jacobson

Open access · greenAbstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Allosteric modulation of purine and pyrimidine receptors.Advances in pharmacology (San Diego, Calif.) · 2011
    Review
  4. Review
  5. Cyclization-activated prodrugs.Molecules (Basel, Switzerland) · 2007
    Review
  6. Agonists and antagonists for P2 receptors.Novartis Foundation symposium · 2006
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Pedro BesadaMolecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-0810, USA.
Liaman Mamedova
Craig J Thomas
Stefano Costanzi
Kenneth A Jacobson
National Institutes of Health · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDSZ01DK031115 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$577k
Chemical Biology Core Facility: Various ProjectsZ01DK070005 · NIDDK · DIABETES, DIGESTIVE, KIDNEY DISEASES · PI THOMAS, CRAIG E · 2005 to 2006
–
Intramural NIH HHS Z01 DK031115Intramural NIH HHS Z01 DK070005
6 · The paper itself

Abstract

Diketopiperazines (DKPs) are a common motif in various biologically active natural products, and hence they may be useful scaffolds for the rational design of receptor probes and therapeutic agents. We constructed a new bicyclic scaffold that combines a DKP bridged with a 10-membered ring. In this way we obtained a three-dimensional molecular skeleton, with several amendable sites that provide a starting point to design a new combinatorial library having diverse substituent groups. Structural variation is based upon the flexibility of alkylation of the nitrogen atoms of the DKP and on the side-chain olefin. We obtained a 10-membered secondary ring through a ring-closure metathesis reaction using the second generation Grubbs catalyst. Rings containing both O-ethers and S-ethers were compared. N-Alkyl or arylalkyl groups were introduced optionally at the two Nalpha-atoms. This is a general scheme that will allow us to test rings of varying sizes, linkages, and stereochemical parameters. The DKP derivatives were tested for activity in astrocytoma cells expressing receptors coupled to phospholipase C. Inhibitory effects were observed for signaling elicited by activation of human nucleotide P2Y receptors but not m3 muscarinic receptors. Compound 20 selectively inhibited calcium mobilization (IC50 value of 486 +/- 16 nM) and phosphoinositide turnover elicited by a selective P2Y1 receptor agonist, but this compound did not compete for binding of a radiolabeled nucleotide-competitive receptor antagonist. Therefore, the new class of DKP derivatives shows utility as pharmacological tools for P2Y receptors.

Indexed as

Bridged Bicyclo CompoundsDiketopiperazinesDimerizationElectrochemistryMagnetic Resonance SpectroscopyMicroscopy, Electron, ScanningMolecular StructureOxidation-ReductionPiperazinesSpectrometry, Mass, Fast Atom BombardmentSpectrophotometry, UltravioletBridged Bicyclo CompoundsDiketopiperazinesPiperazines

Identifiers

PMID15889186
PMCPMC3476468
OpenAlexW1966561225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.